AI enhances prostate cancer treatment outcomes, predicts benefits

A study from UCLA suggests that artificial intelligence (AI) could significantly improve treatment for men with prostate cancer. The research focuses on a procedure called partial gland cryoablation, which targets localized tumors while reducing side effects. The AI tool, named Unfold AI, estimates the volume of prostate tumors accurately. This helps doctors identify patients more likely to benefit from the treatment. The study shows that using AI could reduce treatment failures by over 70%. Dr. Wayne Brisbane, who worked on the study, noted the importance of accurate tumor size measurements for successful treatments. Partial gland cryoablation works by freezing only the cancerous part of the prostate. It aims to eliminate tumors with less damage to surrounding areas, leading to better patient quality of life. The procedure is guided by imaging technology like MRI, allowing doctors to monitor the treatment in real-time. However, existing methods often misjudge tumor size, which can lead to incomplete treatment and cancer returning. Unfold AI addresses this by creating detailed 3D maps of tumors from MRI and biopsy data, helping clinics better assess the correct dimensions and boundaries of the cancer. In a clinical trial involving 204 men at UCLA, doctors used the AI tool to gauge tumor volumes alongside traditional measurements like tumor grade. Results showed that smaller tumors, specifically those under 1.5 cubic centimeters, resulted in better treatment outcomes and lower chances of needing further intervention. Dr. Leonard Marks, a senior author of the study, emphasized that understanding tumor volume is crucial for treatment success. While the initial results are promising, researchers call for larger trials to confirm these findings. This study represents a significant step toward using AI in personalized care for prostate cancer patients.